Houston, TX, USA, For Release: 8th September 2015. Algorics, a provider of clinical analytics solutions and software for the global life sciences industry, today announced that acuity, its analytics solution for risk based monitoring, has been adopted by Lexitas Pharma Services, Inc. The US Ophthalmology-focused CRO will leverage the acuity solution to bring together internal and external data sources in order to provide analytics dashboards and alerts to give the leadership team a real-time picture of key operational parameters and KRI (key risk indicators) and allow operational teams to more easily manage trial performance.
“As Lexitas grows we continue to look for innovative ways to improve efficiency without compromising the high quality and tailored services our clients count on. Implementing acuity will provide us with a timely and comprehensive view of how our portfolio of trials is performing, as well as enable us to manage individual trials in the most effective way,” said Chad Ice, President, Lexitas.
Nick Hargaden, President, Algorics said, “We are delighted that Lexitas has chosen acuity to provide centralized insights into the clinical trials they manage, thus driving operational effectiveness and resource savings.”
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Twice-Yearly Lenacapavir Injections Significantly Reduce HIV Risk, PURPOSE 2 Trial Shows
November 13th 2024Full Phase III PURPOSE 2 trial results suggest that twice-yearly lenacapavir could revolutionize HIV prevention by offering a convenient and effective long-acting option for individuals at risk of infection.